CNTB Overview

Real-time Intelligence: Benzinga Pro offers the fastest news alerts to help traders stay informed and make timely decisions in the stock market.

Exclusive Content: Subscribers gain access to exclusive stories and insights generated by Benzinga reporters, enhancing their trading strategies.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and strategies for market success.

Market Winning Tools: The platform provides tools and resources designed to help traders win in the markets every day.

Clinical Trials Update: Connect Biopharma is actively recruiting participants for its Phase 2 Seabreeze STAT studies targeting acute exacerbations in asthma and COPD, with topline data expected in the first half of 2026.

Regulatory Progress: Simcere, Connect's exclusive licensee in Greater China, has submitted a New Drug Application for rademikibart for atopic dermatitis, which has been accepted by China's NMPA.

Corporate Developments: The company has terminated its American Depositary Receipt program and directly listed its ordinary shares on Nasdaq to enhance visibility and reduce costs.

Financial Overview: Connect Biopharma reported a net loss of $17.2 million for Q3 2025, with cash reserves expected to support operations into 2027, while also noting increased R&D expenses related to ongoing clinical trials.

Analyst Ratings Overview: Top Wall Street analysts have recently updated their ratings on several companies, including upgrades, downgrades, and new initiations.

Korro Bio, Inc.: Clear Street analyst Bill Maughan initiated coverage with a Buy rating and a price target of $93, while the stock closed at $36.45.

THOR Industries, Inc.: Loop Capital analyst Brandon Rolle initiated coverage with a Hold rating and a price target of $110, with shares closing at $103.35.

Connect Biopharma Holdings Limited: BTIG analyst Julian Harrison initiated coverage with a Buy rating and a price target of $10, despite the stock closing at $1.55.

Fastest News Alerts: Benzinga Pro offers real-time intelligence to help traders stay updated and make informed decisions in the stock market.

Exclusive Stories: The platform provides unique stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.

Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, sharing knowledge and strategies.

Market Intelligence: Benzinga Pro is marketed as the fastest and most accurate source of stock market intelligence available.